dexmedetomidine (IN) — Competitive Intelligence Brief

dexmedetomidine (IN) (dexmedetomidine (IN)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Anesthesia and Critical Care.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Anesthesia and Critical Care Small molecule

Target snapshot

dexmedetomidine (IN) (dexmedetomidine (IN)) — Azienda Ospedaliera di Padova. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
dexmedetomidine (IN) TARGET	dexmedetomidine (IN)	Azienda Ospedaliera di Padova	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
dexmedetomidine 0.25 µg/kg IV	dexmedetomidine 0.25 µg/kg IV	American University of Beirut Medical Center	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
alpha methyldopa	alpha methyldopa	Radboud University Medical Center	marketed	Central-acting alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
clonidine (drug) intravenously	clonidine (drug) intravenously	Medical University of Vienna	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Group D : Dexmedetomidine + propofol group	Group D : Dexmedetomidine + propofol group	Seoul National University Hospital	marketed	Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist)	Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
Dexmedetomidine (DEX)	Dexmedetomidine (DEX)	Ain Shams University	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Methadone-dexmedetomidine-ketamine combination	Methadone-dexmedetomidine-ketamine combination	University of Missouri-Columbia	marketed	Anesthetic combination (opioid + alpha-2 agonist + NMDA antagonist)	Mu opioid receptor, alpha-2 adrenergic receptor, NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

1. Allergan · 3 drugs in this class
2. Eye & ENT Hospital of Fudan University · 2 drugs in this class
3. National Cancer Institute, Egypt · 2 drugs in this class
4. The University of Hong Kong · 2 drugs in this class
5. Sindh Institute of Urology and Transplantation · 2 drugs in this class
6. Fayoum University Hospital · 1 drug in this class
7. First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
8. Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
9. Icahn School of Medicine at Mount Sinai · 1 drug in this class
10. KAT General Hospital · 1 drug in this class